Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells - PubMed (original) (raw)
. 2007 May 11;282(19):14048-55.
doi: 10.1074/jbc.M611089200. Epub 2007 Mar 12.
Affiliations
- PMID: 17353198
- DOI: 10.1074/jbc.M611089200
Free article
Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells
Zhenyu Ji et al. J Biol Chem. 2007.
Free article
Abstract
Hedgehog (Hh) signaling is deregulated in multiple human cancers including pancreatic ductal adenocarcinoma (PDA). Because KRAS mutation represents one of the earliest genetic alterations and occurs almost universally in PDA, we hypothesized that oncogenic KRAS promotes pancreatic tumorigenesis in part through activation of the Hh pathway. Here, we report that oncogenic KRAS activates hedgehog signaling in PDA cells, utilizing a downstream effector pathway mediated by RAF/MEK/MAPK but not phosphatidylinositol 3-kinase (PI3K)/AKT. Oncogenic KRAS transformation of human pancreatic ductal epithelial cells increases GLI transcriptional activity, an effect that is inhibited by the MEK-specific inhibitors U0126 and PD98059, but not by the PI3K-specific inhibitor wortmannin. Inactivation of KRAS activity by a small interfering RNA specific for oncogenic KRAS inhibits GLI activity and GLI1 expression in PDA cell lines with activating KRAS mutation; the MEK inhibitors U0126 and PD98059 elicit a similar response. In addition, expression of the constitutively active form of BRAF(E600), but not myr-AKT, blocks the inhibitory effects of KRAS knockdown on Hh signaling. Finally, suppressing GLI activity leads to a selective attenuation of the oncogenic transformation activity of mutant KRAS-expressing PDA cells. These results demonstrate that oncogenic KRAS, through RAF/MEK/MAPK signaling, is directly involved in the activation of the hedgehog pathway in PDA cells and that collaboration between these two signaling pathways may play an important role in PDA progression.
Similar articles
- KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC. Appleman VA, et al. Mol Cancer Res. 2012 Sep;10(9):1228-39. doi: 10.1158/1541-7786.MCR-12-0340-T. Epub 2012 Aug 7. Mol Cancer Res. 2012. PMID: 22871572 Free PMC article. - Stromal response to Hedgehog signaling restrains pancreatic cancer progression.
Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, Fitamant J, Jones PD, Ghanta KS, Kawano S, Nagle JM, Deshpande V, Boucher Y, Kato T, Chen JK, Willmann JK, Bardeesy N, Beachy PA. Lee JJ, et al. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3091-100. doi: 10.1073/pnas.1411679111. Epub 2014 Jul 14. Proc Natl Acad Sci U S A. 2014. PMID: 25024225 Free PMC article. - Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer.
Wei L, Xu Z. Wei L, et al. Int J Cancer. 2011 Jul 15;129(2):275-84. doi: 10.1002/ijc.25673. Epub 2010 Nov 3. Int J Cancer. 2011. PMID: 20839260 - Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C, Cave DD, Papavassiliou AG. Adamopoulos C, et al. Int J Mol Sci. 2024 Jan 28;25(3):1631. doi: 10.3390/ijms25031631. Int J Mol Sci. 2024. PMID: 38338909 Free PMC article. Review. - Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?
Rovida E, Stecca B. Rovida E, et al. Semin Cancer Biol. 2015 Dec;35:154-67. doi: 10.1016/j.semcancer.2015.08.003. Epub 2015 Aug 17. Semin Cancer Biol. 2015. PMID: 26292171 Review.
Cited by
- Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers.
Oh JM, Rajendran RL, Gangadaran P, Hong CM, Jeong JH, Lee J, Ahn BC. Oh JM, et al. Cancers (Basel). 2022 Mar 31;14(7):1782. doi: 10.3390/cancers14071782. Cancers (Basel). 2022. PMID: 35406554 Free PMC article. - The alpha subunit of the G protein G13 regulates activity of one or more Gli transcription factors independently of smoothened.
Douglas AE, Heim JA, Shen F, Almada LL, Riobo NA, Fernández-Zapico ME, Manning DR. Douglas AE, et al. J Biol Chem. 2011 Sep 2;286(35):30714-30722. doi: 10.1074/jbc.M111.219279. Epub 2011 Jul 11. J Biol Chem. 2011. PMID: 21757753 Free PMC article. - Expression of hydrogen sulfide synthases and Hh signaling pathway components correlate with the clinicopathological characteristics of papillary thyroid cancer patients.
Xu Y, Ma N, Wei P, Zeng Z, Meng J. Xu Y, et al. Int J Clin Exp Pathol. 2018 Mar 1;11(3):1818-1824. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31938289 Free PMC article. - GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAFV600E Colorectal Cancer.
Zhang R, Ma J, Avery JT, Sambandam V, Nguyen TH, Xu B, Suto MJ, Boohaker RJ. Zhang R, et al. Front Oncol. 2020 Feb 28;10:241. doi: 10.3389/fonc.2020.00241. eCollection 2020. Front Oncol. 2020. PMID: 32185127 Free PMC article. - DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway.
Singh R, Dhanyamraju PK, Lauth M. Singh R, et al. Oncotarget. 2017 Jan 3;8(1):833-845. doi: 10.18632/oncotarget.13662. Oncotarget. 2017. PMID: 27903983 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous